TCT-103 National variation in post-TAVR antithrombotic therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry®

Oral antiplatelet medications are routinely administered to patients following TAVR, however, there are limited data on the ideal antithrombotic treatment strategy or the patterns of medication use and outcomes in the U.S. Using the STS/ACC TVT Registry we evaluated patients without pre-operative